The three Covid-19 vaccines – Oxford-AstraZeneca, Pfizer-BioNTech, and Moderna have signified the rate of effectiveness of their potential Covid-19 vaccine candidates AZD1222, BNT162b2, and mRNA-1273, respectively.
However, some surprising revelations have been made about the error in the dosage by Oxford-AstraZeneca which has led to raising doubts over the authenticity of the efficacy of their vaccine candidate. Whereas, AstraZeneca CEO Pascal Soriot has asserted that the company is likely to go for one more global trial of the vaccine candidate, according to a Reuters report.
What is Oxford-AstraZeneca Covid-19 vaccine error?
On November 23, AstraZeneca announced the effective results of its vaccine candidate. AstraZeneca said in a statement that two different dosing regimens demonstrated varying efficacy. In participants treated with AZD1222, there were no hospitalisations or severe cases of Covid-19.
When AZD1222 was given as a half dose, followed by a full dose at least one month apart, it resulted in 90 percent vaccine efficacy, and other dosing regimen saw 62 percent efficacy when given as double full doses with a gap of at least one month.
AstraZeneca said in the statement that the combined analysis from both dosing regimens resulted in an average efficacy of 70 percent. It said that an independent Data Safety Monitoring Board had verified the results and more data will be collected.
As soon as this announcement was made, Moncef Slaoui, head of the US Operation Warp Speed program, responsible for looking after the vaccine programme in America, asserted that most of the participants among those who received the regimen of two full doses were of the age group 55 years and above.
What led to the Oxford-AstraZeneca Covid-19 vaccine error?
Around the time when Astra was coming into partnership with Oxford during April end; university researchers were giving doses to trial participants in Britain, stated by the head of AstraZeneca’s non-oncology research and development Mene Pangalos.
The observatory symptoms of this trial were side effects like fatigue, headaches, or arm aches which were milder than expected. It was noted that the dose was under-predicted, therefore the company decided to continue with the half dose and administer the full dose booster shot at the determined time, according to a report of the Reuters.
Oxford also said in a statement about the “difference in the method of measuring the concentration of the Covid-19 vaccine candidate”. The initial vaccine doses given in batches used for the phase 3 trials in the UK to 2,741 UK participants were overestimated.
Oxford said that when a lower dose was used, they had discussions with the regulator and decided to test both sets of lower dose-higher dose and higher dose-higher dose at the time of Phase 3 human trials.
Read: What is eVIN technology? Know about the distribution of Covid-19 vaccines
Read: Covid-19: How to flag false information on Instagram
Read: Arrhythmia: How can modern medicine help you battle it?
